Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts

Cancer

Volumn 118, Issue 3, 2012, Pages 797-803

  Liu, Wei ^a,b   Choueiri, Toni K ^a   Cho, Eunyoung ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CHANNING LABORATORY   (United States)

Author keywords

carcinoma; neoplasms; prospective studies; renal cell; statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CLINICAL TRIAL; COHORT ANALYSIS; CORRELATIONAL STUDY; DOSE RESPONSE; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION; UNITED STATES;

ADULT; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HEALTH OCCUPATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; KIDNEY NEOPLASMS; MALE; MASSACHUSETTS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84856223908     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26338     Document Type: Article

References (32)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7-22.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389.
3. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D,. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008; 52: 1769-1781.
4. Hindler K, Cleeland CS, Rivera E, Collard CD,. The role of statins in cancer therapy. Oncologist. 2006; 11: 306-315.
5. Pahan K,. Lipid-lowering drugs. Cell Mol Life Sci. 2006; 63: 1165-1178.
6. Wong WW, Dimitroulakos J, Minden MD, Penn LZ,. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002; 16: 508-519.
7. Khurana V, Caldito G, Ankem M,. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology. 2008; 71: 118-122.
8. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ,. The risk of cancer in users of statins. J Clin Oncol. 2004; 22: 2388-2394.
9. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA,. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008; 17: 27-36.
10. Coogan PF, Rosenberg L, Strom BL,. Statin use and the risk of 10 cancers. Epidemiology. 2007; 18: 213-219.
11. Kaye JA, Jick H,. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004; 90: 635-637.
12. Hippisley-Cox J, Coupland C,. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database [serial online]. BMJ. 2010; 340: c2197.
13. MRC/BHF Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial (ISRCTN48489393) [serial online]. BMC Med. 2005; 3: 6.
14. Kuoppala J, Lamminpaa A, Pukkala E,. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer. 2008; 44: 2122-2132.
15. Chow WH, Devesa SS,. Contemporary epidemiology of renal cell cancer. Cancer J. 2008; 14: 288-301.
16. Colditz GA, Hankinson SE,. The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer. 2005; 5: 388-396.
17. Rimm EB, Giovannucci EL, Willett WC, et al. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet. 1991; 338: 464-468.
18. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol. 1984; 119: 837-839.
19. Percy C, Van Holten V, Muir C,. International Classification of Disease for Oncology. 2nd ed. Geneva, Switzerland: World Health Organization; 1990.
20. Puckett CD,. The Educational Annotation of ICD-9-CM. Reno, NV: Channel Publishing Ltd.; 1986.
21. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997; 80: 987-989.
22. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS,. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008; 134: 21-28.
23. Joh HK, Willett WC, Cho E,. Type 2 diabetes and the risk of renal cell cancer in women [published online ahead of print May 20, 2011]. Diabetes Care. 2011.
24. Lee JE, Giovannucci E, Smith-Warner SA, Spiegelman D, Willett WC, Curhan GC,. Total fluid intake and use of individual beverages and risk of renal cell cancer in 2 large cohorts. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1204-1211.
25. Lee JE, Giovannucci E, Smith-Warner SA, Spiegelman D, Willett WC, Curhan GC,. Intakes of fruits, vegetables, vitamins A, C, and E, and carotenoids and risk of renal cell cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15: 2445-2452.
26. Lee JE, Hankinson SE, Cho E,. Reproductive factors and risk of renal cell cancer: the Nurses' Health Study. Am J Epidemiol. 2009; 169: 1243-1250.
27. Cox DR,. Regression models and life tables (with discussion). J R Stat Soc B. 1972; 34: 187-220.
28. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Hayakawa M,. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res. 2004; 10: 8648-8655.
29. Woodard J, Sassano A, Hay N, Platanias LC,. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res. 2008; 14: 4640-4649.
30. George DJ, Kaelin WG Jr,. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med. 2003; 349: 419-421.
31. Elewa HF, El-Remessy AB, Somanath PR, Fagan SC,. Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy. 2010; 30: 169-176.
32. Lee KJ, Moon JY, Choi HK, et al. Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. Clin Exp Immunol. 2010; 161: 298-305.